Diversified Trust Co purchased a new stake in West Pharmaceutical Services Inc. (NYSE:WST) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,412 shares of the medical instruments supplier’s stock, valued at approximately $200,000.
Several other large investors have also recently made changes to their positions in WST. AlphaCrest Capital Management LLC acquired a new stake in shares of West Pharmaceutical Services in the first quarter valued at approximately $327,000. Granite Investment Partners LLC acquired a new position in shares of West Pharmaceutical Services during the first quarter valued at approximately $971,000. Trexquant Investment LP increased its stake in shares of West Pharmaceutical Services by 24.9% during the first quarter. Trexquant Investment LP now owns 14,275 shares of the medical instruments supplier’s stock valued at $1,573,000 after acquiring an additional 2,849 shares during the period. Champlain Investment Partners LLC increased its stake in shares of West Pharmaceutical Services by 4.7% during the first quarter. Champlain Investment Partners LLC now owns 594,625 shares of the medical instruments supplier’s stock valued at $65,528,000 after acquiring an additional 26,640 shares during the period. Finally, Mission Wealth Management LP increased its stake in shares of West Pharmaceutical Services by 9.5% during the first quarter. Mission Wealth Management LP now owns 2,606 shares of the medical instruments supplier’s stock valued at $287,000 after acquiring an additional 226 shares during the period. Institutional investors own 91.08% of the company’s stock.
WST has been the topic of a number of research analyst reports. ValuEngine lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Bank of America upgraded shares of West Pharmaceutical Services from an “underperform” rating to a “neutral” rating in a research note on Friday, July 26th. Finally, Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating and set a $158.00 price objective on the stock in a research note on Saturday, August 3rd. Three analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $130.72.
West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $0.89 EPS for the quarter, beating the Zacks’ consensus estimate of $0.72 by $0.17. West Pharmaceutical Services had a net margin of 12.94% and a return on equity of 16.93%. The business had revenue of $469.70 million for the quarter, compared to analyst estimates of $459.90 million. During the same quarter last year, the business earned $0.70 earnings per share. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. Sell-side analysts anticipate that West Pharmaceutical Services Inc. will post 3.07 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 6th. Investors of record on Wednesday, October 23rd will be issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date is Tuesday, October 22nd. West Pharmaceutical Services’s payout ratio is 21.35%.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Recommended Story: Discover Your Risk Tolerance
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.